Image pharmaphorum Editor News Top cancer doctor steps down from posts in industry affiliat... Prominent cancer research doctor José Baselga has stepped down from two posts after failing to be open about his industry affiliations. News Sanofi unveils eczema drug data, as regulators mull label ex... Sanofi has revealed details of research, which forms the basis of filings to extend the use of its eczema drug Dupixent (dupilumab) so it can be used to treat adolescents. News J&J trumpets new data from Tremfya as psoriasis market brace... Humira biosimilars set to launch in EU next month News Pharma outperforms academia at reporting clinical trials - B... Only half of trials reported results despite EU rules Load more results
News Top cancer doctor steps down from posts in industry affiliat... Prominent cancer research doctor José Baselga has stepped down from two posts after failing to be open about his industry affiliations.
News Sanofi unveils eczema drug data, as regulators mull label ex... Sanofi has revealed details of research, which forms the basis of filings to extend the use of its eczema drug Dupixent (dupilumab) so it can be used to treat adolescents.
News J&J trumpets new data from Tremfya as psoriasis market brace... Humira biosimilars set to launch in EU next month
News Pharma outperforms academia at reporting clinical trials - B... Only half of trials reported results despite EU rules
News FDA clears first all-oral combo for first-line CLL treatment AstraZeneca's Calquence and AbbVie/Roche's Venclexta have become the first all-oral, fixed-duration regimen for newly-diagnosed CLL.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
